Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)
US2026049310A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2026049310-A1 |
| Application number | US-202519171501-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 7, 2025 |
| Priority date | Nov 9, 2018 |
| Publication date | Feb 19, 2026 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is directed to methods of reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a). Specifically, a method of reducing the risk of a cardiovascular event in a patient who has established cardiovascular disease with conjugated antisense compound ISIS 681257 or a salt thereof.
First claim
Opening claim text (preview).
1 - 60 . (canceled) 61 . A method of treating a patient, the method comprising administering to the patient a unit dose comprising from about 75 mg to about 85 mg of a compound or pharmaceutically acceptable salt thereof by subcutaneous injection once a month, wherein the compound has the following structure: and wherein the patient has established cardiovascular disease and elevated Lp(a) levels, to thereby reduce the risk of cardiovascular death, myocardial infarction, stroke, or urgent coronary re-vascularization. 62 . The method according to claim 61 , wherein the unit dose comprises about 80 mg of the compound. 63 . The method according to claim 61 , wherein the unit dose comprises 80 mg of the compound. 64 . The method according to claim 61 , wherein the patient has elevated Lp(a) levels ≥70 mg/dL prior to the first administration of the compound. 65 . The method according to claim 61 , wherein the compound is in the form of a sodium salt. 66 . The method according to claim 65 , wherein the compound has the following structure:
Assignees
Inventors
Classifications
Special therapeutic applications · CPC title
Conjugate · CPC title
Gapmers, i.e. of the type ===---=== · CPC title
Antisense · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2026049310A1 cover?
- The present disclosure is directed to methods of reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a). Specifically, a method of reducing the risk of a cardiovascular event in a patient who has established cardiovascular disease with conjugated antisense compound ISIS 681257 or a salt thereof.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Feb 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).